Zealand Pharma A/S (OCSE:ZEAL) Days Sales Outstanding

: 929.61 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Zealand Pharma A/S's average Accounts Receivable for the three months ended in Dec. 2023 was kr236.7 Mil. Zealand Pharma A/S's Revenue for the three months ended in Dec. 2023 was kr23.2 Mil. Hence, Zealand Pharma A/S's Days Sales Outstanding for the three months ended in Dec. 2023 was 929.61.

The historical rank and industry rank for Zealand Pharma A/S's Days Sales Outstanding or its related term are showing as below:

OCSE:ZEAL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.69 Med: 85.79 Max: 472.24
Current: 171.95

During the past 13 years, Zealand Pharma A/S's highest Days Sales Outstanding was 472.24. The lowest was 17.69. And the median was 85.79.

OCSE:ZEAL's Days Sales Outstanding is ranked worse than
80.41% of 888 companies
in the Biotechnology industry
Industry Median: 72.105 vs OCSE:ZEAL: 171.95

Zealand Pharma A/S's Days Sales Outstanding increased from Dec. 2022 (284.49) to Dec. 2023 (929.61).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Zealand Pharma A/S Days Sales Outstanding Historical Data

The historical data trend for Zealand Pharma A/S's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

17.69

44.88

336.16

472.24

126.70

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															284.49	726.30	957.47	72.27	929.61

Competitive Comparison

For the Biotechnology subindustry, Zealand Pharma A/S's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Days Sales Outstanding falls into.

Zealand Pharma A/S Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Zealand Pharma A/S's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (115.622	+	122.359)	/	2 )	/	342.788	*	365
=	118.9905					/	342.788	*	365
=	126.70

Zealand Pharma A/S's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (351.052	+	122.359)	/	2 )	/	23.235	*	365 / 4
=	236.7055					/	23.235	*	365 / 4
=	929.61

Zealand Pharma A/S (OCSE:ZEAL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Zealand Pharma A/S Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (OCSE:ZEAL) Headlines

No Headlines